Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial. (2024)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s12936-024-04878-2
PubMed Identifier: 38383367
Publication URI: http://europepmc.org/abstract/MED/38383367
Type: Journal Article/Review
Volume: 23
Parent Publication: Malaria journal
Issue: 1
ISSN: 1475-2875